发明名称 |
Ophthalmic composition comprising a prostaglandin |
摘要 |
The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle. |
申请公布号 |
US9539262(B2) |
申请公布日期 |
2017.01.10 |
申请号 |
US201514691167 |
申请日期 |
2015.04.20 |
申请人 |
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. |
发明人 |
Khopade Ajay Jaysingh;Halder Arindam;Bhowmick Subhas Balaram |
分类号 |
A61K31/5575;A61K47/14;A61K9/00;A61K9/107;A61K31/00 |
主分类号 |
A61K31/5575 |
代理机构 |
Sughrue Mion, PLLC |
代理人 |
Sughrue Mion, PLLC |
主权项 |
1. A method of reducing intraocular pressure comprising a step of administering an ophthalmic composition comprising 0.005% w/v latanoprost or a pharmaceutically acceptable salt thereof, 0.15% to 0.3% w/v castor oil, 0.2 to 0.75% w/v of polyethylene glycol hydroxystearate, and a pharmaceutically acceptable vehicle, wherein the ratio of oil to polyethylene glycol hydroxystearate is less than 1.0, wherein the composition is in the form of a self-emulsifying micro-emulsion with average droplet size of about 100 nm or less and a zeta potential is between −0.1 mV to −20 mV, wherein the composition does not comprise a cationic surfactant, and wherein the composition does not comprise a quaternary ammonium compound. |
地址 |
Mumbai IN |